Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) announced its earnings results on Thursday. The specialty pharmaceutical company reported ($0.85) earnings per share (EPS) for the quarter, Zacks reports.
Titan Pharmaceuticals Stock Up 14.8 %
TTNP stock opened at $4.19 on Friday. Titan Pharmaceuticals has a twelve month low of $3.03 and a twelve month high of $14.80. The business has a 50 day moving average of $3.62 and a 200 day moving average of $4.08.
Analyst Ratings Changes
Separately, StockNews.com began coverage on Titan Pharmaceuticals in a research report on Monday, March 17th. They set a “sell” rating for the company.
Titan Pharmaceuticals Company Profile
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.
See Also
- Five stocks we like better than Titan Pharmaceuticals
- The How And Why of Investing in Oil Stocks
- Alphabet Stock Becomes a Low-Risk, High-Reward Play
- What Are Trending Stocks? Trending Stocks Explained
- Affirm Stock: Should You Buy the Dip After Walmart Setback?
- How to Invest in Insurance Companies: A Guide
- MarketBeat Week in Review – 03/17 – 03/21
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
